STERIS plc (STE): analysis and signal as of September 3, 2026
In short
The signal on STERIS plc remains weak, with a 3/3 vote and a score of 2.0. Organic growth of 6 % and guidance held for fiscal year 2027 run into unresolved ethylene oxide litigation and a share price still below its 200-day moving average.
- Current signal
- weak (vote 3/3)
- Deterministic score
- +3.5 → signal expected by the scale : moderate (September 10, 2026)
- Layers
- fundamentals : positive, price : positive, risks : –
Triggered rules
| Rule | Weight |
|---|---|
| favors (GARP) a stock whose PEG is below 1, growth not yet paid for | +1.5 |
| favors robust fundamental health (high Piotroski F-Score) | +1.5 |
| penalizes direct holding of US securities in a CTO (US estate tax at death), favors a UCITS ETF domiciled in IE | -1.0 |
| favors a "fast grower" profile, high and durable earnings growth (> 20 %), to be cross-checked against the PEG | +1.0 |
| moderately favors an asset with robust operating profitability (RMW factor), cross-check with accounting quality (possible manipulation) | +0.5 |
Thesis
STERIS is a sterilization company with recurring revenue and a durable competitive advantage. It posts organic growth of 6 % and holds its guidance with adjusted EPS of 11,10-11,30 USD for fiscal year 2027. However, the ethylene oxide litigation remains an unresolved tail risk, with a first trial against the subsidiary Isomedix having ended in a mistrial in January 2025. The long-term trend is not restored, with the share price remaining below its 200-day moving average.
Bull case
Defensive growth is confirmed by the figures. Revenue for the first quarter of fiscal year 2027 stands at 1 492,7 M USD, up 7,3 %, of which 6 % organic. FTD reaches 982,9 M USD, an increase versus fiscal year 2026, and management guidance is maintained. Short interest represents 2,40 % of the float, down 26,7 %. The announcement on 05/08/2026 of a 600 M USD investment in a formulated chemistry facility in North Carolina signals an assertive capital allocation to the core business.
Bear case
The legal tail risk is real. The ethylene oxide process is the subject of mass litigation still active as of July 2026. The January 2025 mistrial leaves Isomedix's liability undecided, and the EPA NESHAP rule requires ongoing compliance investments. The chief executive disposed of 4 428 shares during June 2026 at around 212-214 USD. The 200-day moving average remains above the share price and a negative overnight flow of -4,8 bp/day persists.
Scenarios
The bullish scenario, weighted at 25 %, assumes a recovery of the long-term trend above the 200-day moving average, consistent with analyst consensus. The central scenario, weighted at 50 %, describes a consolidation until the results due in early November 2026. The bearish scenario, weighted at 25 %, corresponds to a return toward the lower end of the recent range if legal pressures persist.
Risks
The main risk lies in the ethylene oxide litigation. An adverse verdict established against Isomedix, accompanied by a quantified provision, would invalidate the thesis, as would a durable break of the long-term trend below the 200-day moving average. The EPA NESHAP regulation also requires ongoing compliance investments. The weak nature of the signal reflects this open litigation and the absence of a recovery of the 200-day moving average.
Market positioning (short sellers)
- Short interest / shares outstanding
- 2.39 %
- Days to cover
- 2.89
- Settlement date
- 2026-08-14
- Source
- FINRA (disseminated on 2026-08-26)
Signal history (last 12 months)
| Date | Signal | New fact |
|---|---|---|
| weak (3/3) | Unchanged. No new aggravating fact dated after 01/09/2026 has emerged on the risk component. The ethylene oxide mistrial of 21/01/2025 and the investment of 05/08/2026 already appeared in the previous layers. The three layers remain positive at medium confidence, which carries the weak signal forward without escalation toward a moderate signal, with the 200-day moving average and the unresolved litigation precluding stronger conviction. This is an informative analysis and not personalized advice. | |
| weak (single draw, outside the three-draw protocol) | unchanged |
Frequently asked questions
What is the current signal on STERIS and what does its 3/3 vote mean?
The signal is weak, with a 3/3 vote and a score of 2.0. This reading reflects the tension between organic growth of 6 %, guidance held for fiscal year 2027, and unresolved ethylene oxide litigation, as well as a share price still below its 200-day moving average. No stronger conviction emerges in this context.
What is the status of the ethylene oxide litigation?
The ethylene oxide process is the subject of mass litigation still active as of July 2026. A first trial against the subsidiary Isomedix ended in a mistrial in January 2025, which leaves its liability undecided. The EPA NESHAP rule also requires the company to make ongoing compliance investments.
Which elements support the bullish thesis?
Revenue for the first quarter of fiscal year 2027 reaches 1 492,7 M USD, up 7,3 %, of which 6 % organic. FTD rises to 982,9 M USD and the adjusted EPS guidance of 11,10-11,30 USD is maintained. Short interest declines by 26,7 % to 2,40 % of the float, and an investment of 600 M USD was announced on 05/08/2026 in North Carolina.
Why is the long-term trend considered not restored?
The 200-day moving average remains above the share price, which indicates that the long-term trend is not restored. A negative overnight flow of -4,8 bp/day persists. The chief executive also disposed of 4 428 shares during June 2026 at around 212-214 USD. These elements temper the reading despite confirmed defensive growth.
Which scenarios are envisaged for the coming months?
The central scenario, weighted at 50 %, describes a consolidation until the results due in early November 2026. The bullish scenario is weighted at 25 % and assumes a recovery of the long-term trend above the 200-day moving average. The bearish scenario, weighted at 25 %, corresponds to a return toward the lower end of the recent range if legal pressures persist.
Sources
The official filings below are the issuer's own, matched to this stock by its identifier (LEI, CIK or ISIN). The figures quoted above come from an automated arbitration: they have not been re-checked one by one.
Automated AI analysis: limitations and transparency
- This content is an automated analysis produced using artificial intelligence. Personal analysis for information purposes — no personalised investment advice. MMR content consists of general research. It does not take account of your financial circumstances, objectives or risk tolerance. Data, analyses and results, including those produced using artificial intelligence, may contain errors, be incomplete or become outdated. No return or outcome is guaranteed. All investments carry a risk of partial or total loss of capital. Past performance and simulations do not predict future results. Before making any decision, check information against original sources and, where necessary, consult an authorised professional. You remain responsible for your investment decisions. This notice does not exclude or limit any liability that cannot legally be excluded or limited.
- Tool and analysis: QDNA, Aurélien Ambert.
- Analysis (arbitration) completed on September 3, 2026; this page was completed on September 3, 2026 at 22:40 (UTC).
- Interests: no position in the stock analysed (STE) is recorded in the data consulted on (UTC). This does not confirm the absence of holdings or other interests. The situation at the analysis publication date has not been reconstructed.
- This declaration covers only recorded positions in this stock; it is not an exhaustive verification of other interests or remuneration.
- Methodology: analysis chain, score formula and scale described on the public methodology page.
- Analysis horizon: 2035.
See also
- Neighbouring stock in the same sector: AbbVie, Inc. (ABBV)
- All analysed stocks
- Public methodology